Ken Griffin Checkpoint Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$1.02 - $10.6 $9,996 - $103,880
-9,800 Reduced 3.9%
241,800 $251,000

Others Institutions Holding CKPT

# of Institutions
3
Shares Held
1.91M
Call Options Held
0
Put Options Held
0
View Full List

About Checkpoint Therapeutics, Inc.

CKPT Quotes by TradingView
  • Ticker CKPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,497,000
  • Market Cap $302M
  • Description
  • Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...
More about CKPT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email